DecaTrex 350mg/ml 10ml Vial by Concentrex Labs

Usage

1. Plan phase duration before starting: Map out blast length (typically 8–12 weeks) and cruise length (8–16 weeks) based on your bloodwork baseline so you know target doses for each phase before drawing the first vial.
2. Calculate your draw volume precisely: At 350 mg/ml, divide your target weekly dose in mg by 350 to determine millilitres needed; use a 1 ml syringe for cruise doses below 0.6 ml to minimise measurement error.
3. Prepare injection site with aseptic technique: Wipe the vial stopper and injection site with 70 % isopropyl alcohol swabs; allow both to air-dry fully before proceeding to avoid introducing contaminants into a multi-dose vial used across many weeks.
4. Administer intramuscularly at consistent intervals: Inject into the glute, vastus lateralis, or deltoid using a 23–25 gauge, 1–1.5 inch needle; maintaining the same weekly injection day(s) supports plasma-level consistency across both protocol phases.
5. Track biomarkers at phase transitions: Schedule a full blood panel — including LH, FSH, total testosterone, haematocrit, lipid profile, and liver enzymes — at the end of each blast phase and at the midpoint of each cruise phase to make evidence-based dose decisions.
6. Store the open vial correctly between uses: Keep the punctured vial at room temperature away from heat and direct light, or refrigerate at 2–8 °C; discard any remaining product 28 days after first puncture regardless of volume remaining.

Warnings

Frequently asked questions

What exactly does a cruise and blast protocol involve when using Nandrolone Decanoate?

A cruise and blast protocol alternates between high-dose blast phases — designed to maximise muscle and strength gains — and lower-dose cruise phases that maintain hormone levels while reducing cumulative physiological stress. Nandrolone Decanoate suits both phases because its long decanoate ester sustains plasma levels across multiple days per injection, eliminating the need for daily or every-other-day administration during either block.

How long should the cruise phase typically last before returning to a blast?

Most experienced practitioners run cruise phases for eight to sixteen weeks, though duration depends on bloodwork markers including haematocrit, lipid panels, and liver enzymes rather than a fixed calendar. A cruise phase should continue until key biomarkers return toward baseline and the athlete feels recovered from the preceding blast; rushing back into a blast before markers normalise increases cumulative health risk over a long-term protocol.

At what point during a blast cycle should you transition down to a cruise dose of DecaTrex?

The transition from blast to cruise is typically triggered by a pre-scheduled blood panel at weeks eight to twelve of the blast, or earlier if side-effect markers — haematocrit above 52 %, significant HDL suppression, or blood-pressure elevation — appear. Because Nandrolone Decanoate has an approximate half-life of six to twelve days, dropping to a cruise dose begins to lower average plasma concentration within the first week of dose reduction, making the transition relatively controlled compared to short-ester compounds.

Why does DecaTrex's 350mg/ml concentration matter specifically for sub-millilitre cruise doses?

At 350 mg/ml, even a 100 mg cruise dose requires only 0.29 ml — a volume that fits precisely within a 0.5 ml or 1 ml insulin-style syringe, allowing more accurate measurement than drawing small volumes from lower-concentration vials. This matters because cruise-phase dosing precision directly affects hormonal stability; inaccurate small-volume draws from dilute solutions introduce proportionally larger dosing errors that can destabilise carefully managed cruise-phase hormone levels.

How should the DecaTrex 10ml vial be stored after the first draw, and how many doses can it realistically yield?

After the rubber septum is first punctured, DecaTrex should be stored upright at room temperature away from direct light, or refrigerated at 2–8 °C if not used within four weeks; the multi-dose vial remains viable for up to 28 days after first use when handled under aseptic technique. At a blast dose of 350 mg per week (1 ml per week) the vial provides ten weeks of blast-phase supply; at a 175 mg cruise dose (0.5 ml per week) the single vial covers twenty weeks, making it highly cost-efficient across a full blast-and-cruise calendar. (2) angle_used

Manufacturer

Concentrex Labs operates under a GMP-certified quality framework in which each product line undergoes independent validation at the formulation, manufacturing, and release stages. The laboratory holds ISO-aligned documentation for its in-process controls, covering raw-material certificate-of-analysis verification, in-process potency monitoring via HPLC, and finished-product LAL endotoxin testing before any batch is approved for distribution. For DecaTrex specifically, the 350 mg/ml specification required documented validation of carrier-oil solubilisation capacity and thermal stability across the anticipated storage temperature range — data retained as part of the batch record accessible to authorised auditors. Vial integrity, fill volume accuracy, and stopper seating are each subject to defined acceptance criteria, with non-conforming units rejected at final inspection rather than reworked, reflecting a quality-over-throughput production philosophy consistent with pharmaceutical-grade parenteral manufacturing standards.